Lexicon Pharmaceuticals Inc has a consensus price target of $5.25, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and Citigroup on April 23, 2024, April 11, 2024, and May 31, 2023. With an average price target of $2.67 between Needham, Needham, and Citigroup, there's an implied 72.04% upside for Lexicon Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/23/2024 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
04/11/2024 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
05/31/2023 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | 416.13% | Citigroup | Yigal Nochomovitz | $6 → $8 | Maintains | Buy | Get Alert |
05/30/2023 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | — | Needham | Joseph Stringer | — | Maintains | Hold | Get Alert |
03/07/2023 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | 93.55% | Jefferies | Andrew Tsai | → $3 | Initiates | → Hold | Get Alert |
11/22/2022 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | 287.1% | Citigroup | Yigal Nochomovitz | $16 → $6 | Maintains | Buy | Get Alert |
08/12/2022 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | 545.16% | Piper Sandler | Yasmeen Rahimi | → $10 | Initiates | → Overweight | Get Alert |
07/01/2022 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.55 | 1190.32% | Citigroup | Yigal Nochomovitz | $18 → $20 | Maintains | Buy | Get Alert |
The latest price target for Lexicon Pharmaceuticals (NASDAQ: LXRX) was reported by Needham on April 23, 2024. The analyst firm set a price target for $0.00 expecting LXRX to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Lexicon Pharmaceuticals (NASDAQ: LXRX) was provided by Needham, and Lexicon Pharmaceuticals reiterated their hold rating.
There is no last upgrade for Lexicon Pharmaceuticals.
There is no last downgrade for Lexicon Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexicon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexicon Pharmaceuticals was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
While ratings are subjective and will change, the latest Lexicon Pharmaceuticals (LXRX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Lexicon Pharmaceuticals (LXRX) is trading at is $1.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.